Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open, Multicentric, Non-Interventional Observational Study Investigating Retention, Seizure Control and Tolerability in Epilepsy Patients With Partial Onset Seizures Receiving Eslicarbazepine Acetate (ESL) in Different Therapy Situations

NCT03082222 is registered in ClinicalTrials.gov with Eisai GmbH as lead sponsor.

NCT NCT03082222
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03082222 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open, Multicentric, Non-Interventional Observational Study Investigating Retention, Seizure Control and Tolerability in Epilepsy Patients With Partial Onset Seizures Receiving Eslicarbazepine Acetate (ESL) in Different Therapy Situations
Lead sponsor
Eisai GmbH
Phase
Observational
Overall status
Completed
Start date
July 31, 2015
Completion date
October 29, 2018
Enrollment
246 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

focal epilepsy